Esperion CCO Eric Warren to depart effective April 18, 2025

Esperion Therapeutics, Inc.

Eric Warren stepping down as Chief Commercial Officer, effective April 18, 2025.
Departure not the result of any disagreement with the Company on operations, policies, or practices.
No successor or interim CCO announced in the filing.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Eric Warren

Chief Commercial Officer

ESPR · Esperion Therapeutics, Inc.

Effective: 2025-04-18
Filed: April 4, 2025, 7:59 PM ET

Eric Warren was stepping down from his position as Chief Commercial Officer of the Company, effective as of April 18, 2025.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Eric Warren departed as Chief Commercial Officer at Esperion Therapeutics, Inc..

Action: stepping down
Role: Chief Commercial Officer

Exact text from the filing

Eric Warren was stepping down from his position as Chief Commercial Officer of the Company, effective as of April 18, 2025.

View on SEC.gov

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-25-016794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.